论文部分内容阅读
目的探究致康胶囊联合注射用埃索美拉唑钠治疗非静脉曲张性上消化道出血的临床疗效.方法选取2015-03/2016-03淄博市第一医院收治的非静脉曲张性上消化道出血患者120例,按治疗方案不同随机分组,为A组(对照组)和B组(治疗组),每组各60例.对照组注射用埃索美拉唑钠(40 mg,2次/d).B组在A组治疗上加用口服致康胶囊(3粒/次,3次/d).两组患者均治疗7 d.观察两组的临床疗效,同时比较两组临床有效率、72 h止血成功率、腹痛缓解时间及不良反应发生率.结果B组的临床总有效率和72 h止血率均比A组高(95.00%vs 83.33%,83.33%vs 71.67%),差异有统计学意义(P<0.05).B组腹痛缓解时间与A组相比较缩短了,差异有统计学意义(P<0.05).B组的不良发生率比A组低(8.33%vs 13.33%),差异无统计学意义(P>0.05).结论致康胶囊联合注射用埃索美拉唑钠治疗非静脉曲张性上消化道出血出血其临床疗效明显,提高止血效果,减轻临床症状,不良反应较少并缩短住院时间,具有一定的应用价值,值得临床推广.
Objective To investigate the clinical efficacy of Zhikang capsule combined with esomeprazole sodium in the treatment of non-variceal upper gastrointestinal bleeding.Methods The clinical data of non-varicose upper gastrointestinal tract admitted to the First Hospital of Zibo City from March 2015 to March 2016 One hundred and twenty patients with hemorrhage were randomly divided into group A (control group) and group B (treatment group), 60 patients in each group.Ejection rate of esomeprazole sodium (40 mg, twice / d) Group B was treated with oral Zhikang capsule (3 capsules / time, 3 times / d) in group A. Both groups were treated for 7 days.The clinical efficacy of the two groups were observed, and the clinical efficacy , The success rate of hemostasis 72 h, the time of abdominal pain relief and the incidence of adverse reactions were observed.Results The total effective rate and the rate of hemostasis at 72 h in group B were higher than those in group A (95.00% vs 83.33%, 83.33% vs 71.67%, respectively) (P <0.05) .The pain relief time of group B was shorter than that of group A (P <0.05), and the incidence of adverse reactions in group B was lower than that of group A (8.33% vs 13.33%) , The difference was not statistically significant (P> 0.05) .Conclusion Zhikang capsule combined with esomeprazole sodium injection for non-variceal hemorrhage of upper gastrointestinal bleeding clinical efficacy was significantly improved hemostatic effect Fruit, reduce clinical symptoms, fewer side effects and shorter hospital stay, has a certain value, is worth clinical promotion.